Dianthus Therapeutics, Inc. short interest in 2022
In 2022, Dianthus Therapeutics, Inc.'s disclosed short interest ran from 1.70% of shares outstanding on 14 Jan 2022 to 0.49% on 30 Nov 2022, a change of -1.21 percentage points. The year's high was 2.98% on 15 Jun 2022 and its low 0.49% on 30 Nov 2022, averaging 1.45% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.93 days on 15 Jun 2022. Full history: Dianthus Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 1.70% (14 Jan 2022)
- End of year
- 0.49% (30 Nov 2022)
- Change
- -1.21 pp
- High
- 2.98% (15 Jun 2022)
- Low
- 0.49% (30 Nov 2022)
- Average
- 1.45%
- Highest days to cover
- 9.93 (15 Jun 2022)
- SEC filings marked
- 9
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 1.70% | 3.08 | results (8-K) |
| 31 Jan 2022 | 1.28% | 1.00 | |
| 15 Feb 2022 | 1.66% | 4.50 | |
| 28 Feb 2022 | 2.21% | 4.69 | |
| 15 Mar 2022 | 2.25% | 5.81 | 10-K filed, results (8-K) |
| 31 Mar 2022 | 1.67% | 4.18 | |
| 14 Apr 2022 | 1.64% | 7.64 | |
| 29 Apr 2022 | 2.49% | 6.10 | |
| 13 May 2022 | 2.41% | 3.42 | |
| 31 May 2022 | 2.80% | 3.88 | 10-Q filed, results (8-K) |
| 15 Jun 2022 | 2.98% | 9.93 | |
| 30 Jun 2022 | 1.47% | 1.55 | |
| 15 Jul 2022 | 0.99% | 2.01 | |
| 29 Jul 2022 | 0.88% | 7.30 | |
| 15 Aug 2022 | 0.82% | 4.97 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 0.70% | 1.71 | |
| 15 Sep 2022 | 0.78% | 1.81 | |
| 30 Sep 2022 | 0.81% | 3.56 | |
| 14 Oct 2022 | 0.71% | 4.02 | |
| 31 Oct 2022 | 0.67% | 4.56 | |
| 15 Nov 2022 | 0.53% | 2.01 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 0.49% | 1.85 |
See also: Dianthus Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.